- Who We Are
- Updates & News
- Standards
- Software Tools
- Network Studies
- Community Forums
- Education
- New To OHDSI?
- Community Calls
- Past Events
- 2023 APAC Symposium
- 2023 Europe Symposium
- 2023 SOS Challenge
- 2023 DevCon
- 2023 Phenotype Phebruary
- 2022 Global Symposium
- 2022 APAC Symposium
- 2022 European Symposium
- 2022 DevCon
- 2021 Global Symposium
- 2021 APAC Symposium
- 2020 Global Symposium
- 2020 APAC Symposium
- Past OHDSI Events
- Asia-Pacific (APAC) Community
- Weekly Community Calls
- Workgroups
- OHDSI Annual Report: Our Journey
- Community Dashboards
- This Week In OHDSI
- OHDSI Publications
- Support & Sponsorship
- 2023 Global Symposium
- Github
- YouTube
- Newsletters
CHARYBDIS 2.0, Early SCYLLA Findings, Vaccine AESI Study Framework Discussed In OHDSI COVID-19 Research Presentation
OHDSI research on COVID-19, which began with a memorable global study-a-thon last March, continues to progress in various ways throughout the world. Leaders in three of the largest network studies on the disease joined the Feb. 23 OHDSI community call to provide updates on these projects.
CHARYBDIS
Project CHARYBDIS (Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2) studies the disease natural history of COVID-19. It attempts to describe the baseline demographics, clinical characteristics, treatments, symptoms and outcomes of interest among individuals with COVID-19 overall and stratified by sex, age and specific comorbidities. Kristin Kostka (IQVIA) shared this update (see right) on the project, including a brief discussion on some topics of interest as the team prepares for CHARYBDIS 2.0.
SCYLLA
Project SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses) studies the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network. Daniel Prieto-Alhambra (University of Oxford) discussed the rationale of the study, went over some of the preliminary findings (in this case, heparin vs. aspirin) and expected challenges of this work, and also discussed ways to build on the study moving forward in this presentation.
Vaccine AESI Study
Last year, OHDSI was awarded a $10 million contract from the U.S. Food and Drug Administration (FDA) to provide support to the Biologics Effectiveness and Safety (BEST) program. George Hripcsak (Columbia University) shared this presentation on community work researching COVID-19 Vaccine Adverse Events of Special Interest (AESI) Background Rates. This presentation highlights the framework of the research, differences in the EMA/FDA protocols, outcomes being studied, early results, and more.
